Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Net income	$ 131	$ 93
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	390	425
Accretion of financing instruments and amortization of prepaid financing costs	237	235
Impairment charge on investment in iBio, Inc.	152	139
Change in fair value of derivative instruments	21	133
Allowance for doubtful accounts	(7)	(13)
(Gain) loss on sale of property and equipment	(4)	6
Decrease (increase) in:
Accounts receivable	248	(371)
Inventories	733	(1,140)
Prepaid expenses and other current assets	36	81
(Decrease) increase in:
Accounts payable	(247)	(598)
Accrued expenses and other current liabilities	187	(428)
Net cash provided by (used in) operating activities	1,877	(1,438)
Cash flows from investing activities:
Purchase of property and equipment	(182)	(30)
Proceeds from sale of property and equipment		19
Net cash used in investing activities	(182)	(11)
Cash flows from financing activities:
Advances under revolving credit facility	32,341	34,714
Repayments of advances under revolving credit facility	(32,763)	(32,848)
Repayments under term note payables	(834)	(496)
Repayments under capitalized lease obligations	(47)	(11)
Proceeds from exercise of employee stock options	4
Net cash (used in) provided by financing activities	(1,299)	1,359
Net increase (decrease) in cash	396	(90)
Cash at beginning of fiscal year	55	145
Cash at end of fiscal year	451	55
Supplemental disclosures of cash flow information:
Interest	716	671
Income taxes	7	17
Supplemental disclosures of non-cash transactions:
Accretion on embedded derivative feature of Convertible Note Payable	108	106
Financing on capitalized lease obligations	$ 72	$ 68